Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability

Core Insights - eXoZymes Inc. has achieved a significant validation milestone for its cell-free biomanufacturing platform through a successful pilot scale run conducted by Cayman Chemical, demonstrating the technology's scalability and reliability [1][3] Group 1: Technology Validation - Cayman Chemical utilized eXoZymes' technology transfer package to scale up from a one-liter setup to a 100-liter pilot run, successfully managing real-world conditions that typically challenge enzyme-based processes [2] - The pilot run produced over 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) with a purity of 99.6%, showcasing a high level of efficiency with a 99% conversion rate of feedstock to end product [2][3] Group 2: Industry Impact - The successful pilot run is expected to facilitate partnerships for formulation development, product validation, and application-specific testing, allowing companies to move beyond feasibility studies [3][4] - eXoZymes aims to lead the market in biomanufacturing by offering advanced enzymes, termed "exozymes," which can replace traditional petrochemical processes and enhance sustainability [7][8]